Plain-English translation of NCT06632977 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The PREDICT trial is testing whether matching advanced prostate cancer patients to specific treatments based on their cancer's genetic makeup works better than standard care. Researchers will analyze genetic changes in your cancer tissue or blood and assign you to one of three treatment arms: , a combination of and , or a physician's choice of treatment. The goal is to find out which approach helps patients live longer and stay healthy longer.
Advanced prostate cancer that no longer responds to hormone therapy is very hard to treat, and doctors don't yet have a reliable way to know which patients will benefit from which treatments. This trial aims to solve that problem by using genetic information about each patient's specific cancer to predict which treatment will work best.
You likely qualify if…
You likely don't qualify if…
First, researchers will review your existing cancer tissue or blood samples to identify genetic changes in your cancer. Based on those genetic findings, you will be assigned to receive one of three treatments: a daily oral medication, chemotherapy infusions every 3 weeks, or a physician-selected treatment. Throughout the trial, you will have regular imaging scans (MRI, CT, or bone scans) every few weeks or months to track how your cancer responds, blood tests to check your PSA levels, and follow-up visits to monitor side effects. The study lasts as long as your treatment is working or until side effects become too difficult to manage.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
United States